Survodutide is an investigational, once-weekly injectable being developed for obesity and for fatty-liver disease. It is a “dual agonist” — a single molecule that switches on two receptors at once: the GLP-1 receptor (the target behind Wegovy and Ozempic) and the glucagon receptor. That second action is what makes survodutide unusual, because glucagon signalling works directly inside the liver. Developed by Boehringer Ingelheim together with Zealand Pharma, survodutide is not approved by the FDA or any other regulator and cannot be prescribed or bought — it exists only inside clinical trials.
This guide sits inside our wider coverage of metabolic medicine. If you are new to the category, start with our plain-language GLP-1 explainer and the full GLP-1 guide, then see how the field is shaping up in our pipeline timeline. Survodutide belongs to the same emerging wave as retatrutide, CagriSema and mazdutide. Its liver story connects most closely to GLP-1 and fatty liver, and its weight story to everything in weight & metabolism.
How survodutide works: two hormones, one injection
Approved weight drugs like semaglutide act on a single receptor, GLP-1, which reduces appetite, slows stomach emptying and steadies blood sugar. Tirzepatide (Mounjaro / Zepbound) adds a second gut hormone, GIP. Survodutide takes a different second target: glucagon.
Glucagon is best known for raising blood sugar, but in a molecule engineered to be biased toward GLP-1, its other metabolic effects come to the fore. Glucagon-receptor activation is thought to increase energy expenditure (the calories your body burns at rest) and, critically, to act directly on liver cells to mobilise and burn stored fat. Meanwhile the GLP-1 arm suppresses appetite and offsets glucagon’s blood-sugar-raising tendency, keeping glucose control safe. That two-front design is the reason researchers are testing the same drug for two problems that often travel together: obesity and insulin resistance above the waist, and fat and inflammation inside the liver.
Survodutide at a glance
| Attribute | Detail |
|---|---|
| Mechanism | Once-weekly injectable dual agonist of the GLP-1 and glucagon receptors; the glucagon arm acts directly on the liver |
| Also known as | BI 456906 |
| Developer | Boehringer Ingelheim (development and commercialisation), licensed from Zealand Pharma |
| Studied for | Obesity / overweight, and MASH (metabolic dysfunction-associated steatohepatitis) with liver fibrosis |
| Strongest signal so far | ~15–19% weight loss in phase 2; up to 16.6% at 76 weeks in phase 3 topline (SYNCHRONIZE-1); MASH improved in up to 62% vs 14% on placebo in phase 2 |
| Regulatory status | Investigational — not approved by the FDA or anywhere else; FDA Breakthrough Therapy designation for MASH (2024); phase 3 trials ongoing |
| Availability | Not prescribable or purchasable; clinical trials only |
What the obesity trials show
Phase 2 first. In a randomised, placebo-controlled dose-finding trial published in The Lancet Diabetes & Endocrinology, once-weekly survodutide produced average body-weight reductions of about 15% at 46 weeks at the highest studied dose, rising to roughly 19% among participants who reached and tolerated that dose.[1] For a mid-stage study, that put survodutide firmly in the same efficacy conversation as the leading approved drugs.
Those results triggered a full phase 3 programme. In April 2026, Boehringer Ingelheim and Zealand Pharma reported topline results from SYNCHRONIZE-1, the first large phase 3 obesity trial. Adults with obesity or overweight but without type 2 diabetes lost up to an average of 16.6% of body weight at 76 weeks, versus 3.2% on placebo — a statistically significant difference, with roughly 85% of treated participants losing at least 5%.[2] Follow-up analyses presented in mid-2026 suggested most of the loss came from fat rather than lean tissue, with large drops in visceral (belly) and liver fat. A companion trial in people who also have type 2 diabetes, SYNCHRONIZE-2, is still running.
Topline results are not the same as approval. Full peer-reviewed data, longer safety follow-up and regulatory review all still lie ahead. And like every drug in this class, obesity is treated as a chronic condition, not something “cured” in a course of treatment: the trials keep people on the drug, and weight tends to return when GLP-1–based treatment stops — a pattern we cover in what happens when you stop and weight regain.
Why the glucagon arm matters for fatty liver
Survodutide’s most distinctive data are in the liver. The condition is MASH — metabolic dysfunction-associated steatohepatitis, the more serious form of fatty-liver disease in which fat build-up drives inflammation and scarring (fibrosis). It is common, frequently under-diagnosed, and disproportionately affects people with obesity, type 2 diabetes and — as we explain below — women after menopause.
In a 48-week phase 2 trial published in the New England Journal of Medicine, adults with biopsy-confirmed MASH and fibrosis received survodutide or placebo. The headline results:
| Endpoint at 48 weeks | Survodutide (4.8 mg) | Placebo |
|---|---|---|
| MASH improved without worsening fibrosis | 62% | 14% |
| Fibrosis improved by at least one stage | ~36% | 22% |
| Liver fat reduced by at least 30% | 67% | 14% |
Improvement in MASH without worsening of fibrosis reached 62% at the 4.8 mg dose versus 14% on placebo, and a meaningful share saw fibrosis itself improve by at least one stage.[3] Gastrointestinal side effects were common and dose-related — nausea, diarrhoea and vomiting — consistent with the wider GLP-1 class. On the strength of these findings the FDA granted survodutide Breakthrough Therapy designation for non-cirrhotic MASH in 2024, and two phase 3 liver trials (LIVERAGE and LIVERAGE-Cirrhosis) opened, together enrolling several thousand people.
Context matters. As of 2026, the only FDA-approved MASH medicine is resmetirom (Rezdiffra), a thyroid-hormone-receptor drug — not a GLP-1. Survodutide, if it is approved, would work by a different mechanism, which is one reason the fatty-liver field is watching it closely. For the bigger picture of how gut-hormone drugs affect the liver, see GLP-1 and fatty liver.
How survodutide compares with other next-generation drugs
Survodutide is one of several “multi-target” metabolic drugs racing through trials. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) with the largest weight-loss numbers reported so far. CagriSema pairs semaglutide with the amylin analogue cagrilintide. Mazdutide is another GLP-1/glucagon dual agonist, furthest along in China. What sets survodutide apart is how deliberately its glucagon activity has been aimed at the liver, and how strong its dedicated MASH data are. None of these four is FDA-approved; all remain investigational. Our pipeline timeline tracks where each one stands.
What this means for women in midlife
Fatty-liver disease is often framed as a men’s problem, but the risk profile shifts around menopause. As oestrogen falls, women store more fat viscerally and in the liver, and rates of fatty-liver disease climb — a change that overlaps with the weight gain many women notice in midlife and with wider shifts in heart and metabolic health. Women with PCOS and insulin resistance carry higher fatty-liver risk earlier. A drug that targets both stubborn weight and liver fat is therefore especially relevant to women’s midlife health — which is why we track it, even though it is not yet something anyone can take. If weight and metabolic changes are affecting you now, our coverage of GLP-1s for menopausal weight gain and today’s approved options is the practical place to start; you can also check the GLP-1 eligibility tool.
One caution worth carrying over from the approved drugs: muscle as well as fat can be lost on GLP-1–based treatment, so protein intake and resistance training matter — see GLP-1 and muscle loss.
Is survodutide available? The honest status
No. Survodutide is investigational. It has no FDA approval, no approval anywhere else in the world, and is not sold, prescribed or dispensed outside registered clinical trials. There is no legitimate way to buy it, and any product marketed as “survodutide” outside a trial should be treated as unverified and unsafe. There is no established dose, and this article gives none, because dosing is set by trial protocols and, ultimately, by regulators and prescribers. If you are interested in taking part in research, that is a conversation to have with a doctor or a registered trial site — not a purchase to make online.
When to see a doctor
Survodutide cannot be part of your care yet, but the conditions it targets deserve attention now. Talk to a clinician if you have persistent upper-right abdominal discomfort, unexplained fatigue, abnormal liver blood tests, or risk factors for fatty-liver disease such as obesity, type 2 diabetes or high triglycerides. Because early MASH is usually silent, ask specifically about liver assessment if you carry those risks — diagnosis is made by a clinician using blood tests, imaging and sometimes a biopsy, not by any at-home kit or by this page. If you are weighing approved weight or metabolic treatments, our find-care directory and weight & metabolism hub can help you prepare for that visit.
Survodutide is not FDA-approved. This article is educational and is not medical advice, a diagnosis, or a recommendation to start, stop or switch any medication. Decisions about weight or liver treatment should be made with a qualified clinician.
